ReviewFrontiers in oncology2026
The role and research progress of FGF21 in breast cancer: a review.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the molecular mechanisms, functional controversies, and clinical significance of Fibroblast Growth Factor 21 (FGF21) in the context of breast cancer. Methods: A comprehensive literature search was conducted across databases including PubMed and CNKI to summarize recent advances regarding FGF21 in metabolic reprogramming and immune microenvironment remodeling. Results: FGF21 primarily serves as a pro-tumorigenic factor in breast cancer through several key mechanisms: (1) Metabolic Reprogramming: It activates the ERK1/2-SENP2 axis to upregulate CD36, which enhances fatty acid oxidation to fuel tumor metastasis. (2) Immune Evasion: It induces CD8 Conclusion: FGF21 acts as a pivotal bridge connecting systemic metabolism with local tumor behavior. Future research should focus on developing precision intervention strategies that preserve its systemic metabolic benefits while selectively blocking its local oncogenic effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.